Evolving therapeutic paradigms for multiple myeloma: back to the future

References

• Nerlich AG, Rohrbach H, Bachmeier B, . Malignant tumors in two ancient populations: an approach to historical tumor epidemiology. Oncol Rep 2006;16:197–202.
   PubMed Web of Science ®Google Scholar
• Raab MS, Podar K, Breitkreutz I, . Multiple myeloma. Lancet 2009;374:324–339.
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales MB, Mateo G, . New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586–2592.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, . Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412–5417.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, . Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–1127.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Steensma DP. History of multiple myeloma. Recent Results Cancer Res 2011;183:3–23.
   PubMedGoogle Scholar
• McArthur JR, Athens JW, Wintrobe MM, . Melphalan and myeloma. Experience with a low-dose continuous regimen. Ann Intern Med 1970;72:665–670.
   PubMed Web of Science ®Google Scholar
• Harrington WJ, Moloney WC. The treatment of multiple myeloma with urethane. Cancer 1950;3:253–271.
   Web of Science ®Google Scholar
• Speed DE, Galton DA, Swan A. Melphalan in the treatment of myelomatosis. Br Med J 1964;1:1664–1669.
   PubMed Web of Science ®Google Scholar
• Snapper I. On the influence of stilbamidine upon multiple myeloma. J Mt Sinai Hosp NY 1946;13:119–127.
   PubMedGoogle Scholar
• Scott RB. Cancer chemotherapy--the first twenty-five years. Br Med J 1970;4:259–265.
   PubMed Web of Science ®Google Scholar
• Blokhin N, Larionov L, Perevodchikova N, . [Clinical experiences with sarcolysin in neoplastic diseases]. Ann NY Acad Sci 1958;68:1128–1132.
   PubMed Web of Science ®Google Scholar
• Myelomatosis: comparison of melphalan and cyclophosphamide therapy. Br Med J 1971;1:640–641.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Bergsagel DE, Migliore PJ, . Melphalan therapy for plasma cell myeloma. Blood 1968;31:1–10.
   PubMed Web of Science ®Google Scholar
• Bergsagel DE, Griffith KM, Haut A, . The treatment of plasma cell myeloma. Adv Cancer Res 1967;10:311–359.
   PubMedGoogle Scholar
• Alexanian R, Haut A, Khan AU, . Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680–1685.
   Google Scholar
• Costa G, Engle RL, Schilling A, . Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med 1973;54:589–599.
   Web of Science ®Google Scholar
• Remission maintenance therapy for multiple myeloma. Southwest Oncology Group Study. Arch Intern Med 1975;135:147–152.
   PubMedGoogle Scholar
• Trotta PP. Preclinical biology of alpha interferons. Semin Oncol 1986;13:3–12.
   PubMed Web of Science ®Google Scholar
• Edwards BS, Hawkins MJ, Borden EC. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Cancer Res 1984;44:3135–3139.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415–1421.
   PubMed Web of Science ®Google Scholar
• Du Z, Wei L, Murti A, . Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. J Cell Biochem 2007;102:1087–1094.
   PubMed Web of Science ®Google Scholar
• Creasey AA, Bartholomew JC, Merigan TC. Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 1980;77:1471–1475.
   PubMed Web of Science ®Google Scholar
• Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91:1198–1205.
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Aahre A, Bjorkholm M, . Interferon therapy in myelomatosis. Lancet 1979;2:697.
   PubMed Web of Science ®Google Scholar
• Ahre A, Bjorkholm M, Mellstedt H, . Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984;68:1331–1338.
   PubMedGoogle Scholar
• Khoo TL, Vangsted AJ, Joshua D, . Interferon-alpha in the treatment of multiple myeloma. Curr Drug Targets 2011;12:437–446.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Avvisati G, Amadori S, . Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430–1434.
   PubMed Web of Science ®Google Scholar
• Corso A, Nozza A, Lazzarino M, . Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. Haematologica 1999;84:336–341.
   PubMed Web of Science ®Google Scholar
• Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11:1427–1436.
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113: 1020–1034.
   PubMed Web of Science ®Google Scholar
• Quesada JR, Talpaz M, Rios A, . Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234–243.
   PubMed Web of Science ®Google Scholar
• Valentine AD, Meyers CA, Kling MA, . Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998;25:39–47.
   PubMed Web of Science ®Google Scholar
• Floyd JD, Nguyen DT, Lobins RL, . Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685–7696.
   PubMed Web of Science ®Google Scholar
• Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol 1998;25:9–13.
   PubMed Web of Science ®Google Scholar
• Case DC Jr, Sonneborn HL, Paul SD, . Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986;70: 1251–1254.
   PubMedGoogle Scholar
• Blade J, San Miguel JF, Escudero ML, . Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998;12:1144–1148.
   PubMed Web of Science ®Google Scholar
• Schaar CG, Kluin-Nelemans HC, Te Marvelde C, . Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005;16:634–639.
   PubMed Web of Science ®Google Scholar
• Moalli PA, Rosen ST. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma 1994;15:363–374.
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 1999;457:593–605.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484–489.
   PubMed Web of Science ®Google Scholar
• Greenstein S, Ghias K, Krett NL, . Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8:1681–1694.
   PubMed Web of Science ®Google Scholar
• Frankfurt O, Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 2004;16:553–563.
   PubMed Web of Science ®Google Scholar
• Salmon SE, Crowley JJ, Balcerzak SP, . Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998;16:890–896.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Dimopoulos M, . Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 2000;65:204–209.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Crowley JJ, Grogan TM, . Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163–3168.
   PubMed Web of Science ®Google Scholar
• McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822–824.
   PubMed Web of Science ®Google Scholar
• Selby P, Zulian G, Forgeson G, . The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies. Hematol Oncol 1988;6:173–179.
   PubMed Web of Science ®Google Scholar
• Westbury G, Humble JG, Newton KA, . Disseminated malignant melanoma: response to treatment by massive dosage of a cytotoxic agent combined with autogenous marrow replacement. Lancet 1959;1:968–969.
   PubMed Web of Science ®Google Scholar
• Ariel IM, Pack GT. Treatment of disseminated melanoma with phenylalanine mustard (melphelan) and autogenous bone marrow transplants. Surgery 1962;51:583–591.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Alexanian R, Dicke KA, . High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869–872.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Hall R, Zander A, . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298–1301.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Naucke S, . Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998;21:1101–1107.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot GJ, van Rhee F, . Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158–164.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, . Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434–2441.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Svensson H, Cavo M, . Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209–216.
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B, Iacobelli S, Hegenbart U, . Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011;29:3016–3022.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Pasquini MC, Logan B, . Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011;12:1195–1203.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S, . Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289–3294.
   PubMed Web of Science ®Google Scholar
• Kotla V, Goel S, Nischal S, . Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4085.
   PubMed Web of Science ®Google Scholar
• Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971–978.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, . Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman S, Gertz MA, . Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–4323.
   PubMed Web of Science ®Google Scholar
• List AF. Lenalidomide--the phoenix rises. N Engl J Med 2007;357:2183–2186.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, . Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021–1030.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schmidt-Wolf I, Sonneveld P, . Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124–127.
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince HM, Roberts AW, . Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788–1793.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Pineda-Roman M, van Rhee F, . Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008;112:3115–3121.
   PubMed Web of Science ®Google Scholar
• Hahn-Ast C, von Lilienfeld-Toal M, van Heteren P, . Improved progression-free survival and overall survival with thalidomide maintenance therapy in multiple myeloma: a meta-analysis of randomized trials in 2274 patients. Haematologica 2010;95(Suppl. 2): Abstract 0942.
   Google Scholar
• Beksac M, Haznedar R, Firatli-Tuglular T, . Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011;86: 16–22.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, . Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–831.
   PubMed Web of Science ®Google Scholar
• Waage A, Gimsing P, Fayers P, . Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405–1412.
   PubMed Web of Science ®Google Scholar
• Wijermans P, Schaafsma M, Termorshuizen F, . Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160–3166.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM, . Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107–3114.
   PubMed Web of Science ®Google Scholar
• Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17:1264–1277.
   PubMed Web of Science ®Google Scholar
• Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med 2011;62:249–264.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Attal M, Crowley J, . Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010;28:1209–1214.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Chen CI, Howson-Jan K, . Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004;10:8170–8176.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Trudel S, Bahlis N, . A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial. Blood 2010;116(Suppl. 1): Abstract 2039.
   Google Scholar
• Abdelkefi A, Ladeb S, Torjman L, . Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008;111: 1805–1810. Retraction in Blood 2009;113:6265.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Gregory WM, Davies FE, . The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012;119:7–15.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Tothova E, . Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010;95:1548–1554.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, van Rhee F, . Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 2010;28:3023–3027.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, van der Holt B, Zweegman S, . A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115: 1113–1120.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, . Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, . Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Delforge M, Catalano J, . A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens. Blood 2010;116(Suppl. 1): Abstract 2310.
   Google Scholar
• Palumbo A, Gay F, Falco P, . Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800–807.
   PubMed Web of Science ®Google Scholar
• Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010;24(Suppl. 1):S13–S19.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Heintel D, Zhang LH, . Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011;154:325–336.
   PubMed Web of Science ®Google Scholar
• Heintel D, Zojer N, Schreder M, . Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008;22:441–445.
   PubMed Web of Science ®Google Scholar
• Lioznov M, El-Cheikh J Jr, Hoffmann F, . Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010;45:349–353.
   PubMed Web of Science ®Google Scholar
• van Heteren P, Renz O, Hahn-Ast C, . Activation of innate immunity in patients receiving combination therapy with lenalidomide (Revlimid), cyclophosphamide and low-dose dexamethasone (RCd) for newly diagnosed or relapsed/refractory myeloma. Haematologica 2010;95(Suppl. 2):Abstract 0352.
   Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, . Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, . Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759–1769.
   PubMed Web of Science ®Google Scholar
• Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011;365:2241–2242.
   PubMed Web of Science ®Google Scholar
• Thomas A, Mailankody S, Korde N, . Second malignancies after multiple myeloma: from1960s to 2010s. Blood2012;119: 2731–2737.
   Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, . Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615–2622.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349–360.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, . The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519–4527.
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Catley LP, Hideshima T, . Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996–5000.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, . The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011;10:2034–2042.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez JM, Hernandez MT, . Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165–2172.
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Garcia-Sanz R, Golvano E, . Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127:159–164.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martinez-Lopez J, . Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934–941.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, . Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101–5109.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf I, van der Holt B, . HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 2010;116(Suppl. 1):Abstract 2040.
   Google Scholar
• Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205–3211.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szymonifka J, Anaissie E, . Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010;116:1220–1227.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Tan D, Ong KH, Koh LP, . The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. Eur J Haematol 2012;89:136–144.
   PubMed Web of Science ®Google Scholar
• Moreau P, Rajkumar SV. “Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?”. Leuk Res 2012;36:677–681.
   PubMed Web of Science ®Google Scholar
• Badros AZ. Lenalidomide in myeloma--a high-maintenance friend. N Engl J Med 2012;366:1836–1838.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Kuehl WM, Balakumaran A, . Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 2010;10: 248–257.
   PubMed Web of Science ®Google Scholar